Coexistence of guanidinoacetate methyltransferase (GAMT) deficiency and neuroleptic malignant syndrome without creatine kinase elevation


Ayanoglu M., Korgali E., Sezer T., Aydin H. I. , Sonmez F. M.

BRAIN & DEVELOPMENT, vol.42, no.5, pp.418-420, 2020 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 42 Issue: 5
  • Publication Date: 2020
  • Doi Number: 10.1016/j.braindev.2020.02.001
  • Journal Name: BRAIN & DEVELOPMENT
  • Journal Indexes: Science Citation Index Expanded, Scopus, Academic Search Premier, BIOSIS, EMBASE, MEDLINE, Psycinfo
  • Page Numbers: pp.418-420

Abstract

We describe the first child with guanidinoacetate methyltransferase (GAMT) deficiency who developed neuroleptic malignant syndrome (NMS) after the treatment of risperidone without elevated creatine kinase (CK) levels.